Prospective, multi-centric, randomized open-label, two arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-033 / Erbitux® in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck

Trial Profile

Prospective, multi-centric, randomized open-label, two arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TPR-033 / Erbitux® in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Cetuximab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Reliance Life Sciences
  • Most Recent Events

    • 31 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top